Trenchant BioSystems

Trenchant BioSystems was a biotechnology company focused on developing a bio-artificial pancreas for the treatment of Type 1 Diabetes. The company's primary technology centered on a proprietary encapsulation device designed to house and protect transplanted islet cells from immune rejection, potentially eliminating the need for lifelong immunosuppressant drugs. By creating a perm-selective barrier, the system allowed for the diffusion of oxygen, nutrients, and insulin while blocking immune cells and antibodies. Although the company is currently inactive, its work represented a significant effort in the field of regenerative medicine and cell-based delivery systems. The company was founded by Dr. Jonathan Lakey, a pioneer in islet transplantation, to translate academic research into clinical solutions.